RecruitingNot ApplicableNCT07405931

Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients


Sponsor

Ulsan University Hospital

Enrollment

414 participants

Start Date

Jul 9, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.


Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a digital monitoring program using a smartphone app (called ePRO — electronic patient-reported outcomes) combined with structured telenursing support can help cancer patients manage the side effects of chemotherapy more effectively from home. **You may be eligible if...** - You are 19 years or older - You have been diagnosed with early or advanced gastric (stomach), lung, breast, or colon cancer - You are about to start your first cycle of a new chemotherapy regimen - You can use a smartphone without difficulty - You can read and understand Korean **You may NOT be eligible if...** - You have difficulty communicating due to cognitive, visual, or hearing impairment - You cannot read, write, or understand Korean - Your doctor determines you are otherwise not suitable for the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERStandardized Telenursing

Within Smart Cancer Care Plus, predefined criteria are applied to trigger standardized telenursing interventions. When patients report symptoms of Grade 3 or higher severity, or when a scheduled weekly symptom report is not submitted within 48 hours of the designated reporting date, a structured telephone counseling session is initiated. This process is intended to ensure timely clinical follow-up, support appropriate self-management, and prevent the progression of unmanaged adverse events.

OTHERSmart Cancer Care Plus

Smart Cancer Care Plus is a digital platform for patient-reported symptom monitoring and management, developed for individuals receiving chemotherapy. The system enables structured reporting of chemotherapy-related adverse events and provides standardized information regarding the severity grading of symptoms, accompanied by evidence-based self-management strategies. This intervention is intended to promote systematic symptom monitoring and to facilitate timely clinical responses to adverse events.


Locations(5)

Kosin University Gospel Hospital

Busan, South Korea

National Cancer Center, Korea

Goyang, South Korea

Gachon University Gil Medical Center

Incheon, South Korea

Gyeongsang National University

Jinju, South Korea

Ulsan University Hospital

Ulsan, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07405931


Related Trials